Estimating the proportion of patients infected with HIV who will die of comorbid diseases.

[1]  J. Bartlett,et al.  Primary care for patients infected with human immunodeficiency virus , 2001, Journal of General Internal Medicine.

[2]  V. Stone,et al.  Relation of physician specialty and HIV/AIDS experience to choice of guideline-recommended antiretroviral therapy , 2001, Journal of General Internal Medicine.

[3]  Neil S. Wenger,et al.  Specialty training and specialization among physicians who treat HIV/AIDS in the United States , 2007, Journal of General Internal Medicine.

[4]  Adeeba Kamarulzaman,et al.  AIDS Res Hum Retroviruses , 2006 .

[5]  Mark S Roberts,et al.  Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[6]  D. Vlahov,et al.  A PROSPECTIVE STUDY OF ADHERENCE AND VIRAL LOAD IN A LARGE MULTI-CENTER COHORT OF HIV-INFECTED WOMEN , 2002, AIDS.

[7]  Mary Young,et al.  Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. , 2002, The American journal of medicine.

[8]  Milton C Weinstein,et al.  Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. , 2002, Archives of internal medicine.

[9]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[10]  A. Mocroft,et al.  Erratum: A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study (Journal of Infectious Disease (2002) 185 (178-187)) , 2002 .

[11]  M. Weinstein,et al.  TREATMENT FOR PRIMARY HIV INFECTION: PROJECTING OUTCOMES OF IMMEDIATE, INTERRUPTED, OR DELAYED THERAPY , 2002, Journal of acquired immune deficiency syndromes.

[12]  A. Mocroft,et al.  A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. , 2002, The Journal of infectious diseases.

[13]  C. Sabin,et al.  Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals , 2001, AIDS.

[14]  Julio S. G. Montaner,et al.  Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. , 2001, JAMA.

[15]  M. Weinstein,et al.  Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. , 2001, American journal of public health.

[16]  R. Salamon,et al.  Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. , 2001 .

[17]  R. Salamon,et al.  Clinical, Biologic, and Behavioral Predictors of Early Immunologic and Virologic Response in HIV‐Infected Patients Initiating Protease Inhibitors , 2001, Journal of acquired immune deficiency syndromes.

[18]  Elena Losina,et al.  Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness , 2001, Annals of Internal Medicine.

[19]  M C Weinstein,et al.  The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.

[20]  N. Hansen,et al.  Zidovudine and Stavudine Sequencing in HIV Treatment Planning: Findings From the CHORUS HIV Cohort , 2001, Journal of acquired immune deficiency syndromes.

[21]  C. Sabin,et al.  The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load , 2000, AIDS.

[22]  M. Kazatchkine,et al.  Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy , 2000, Annals of Internal Medicine.

[23]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[24]  M. Kitahata,et al.  Physician Experience in the Care of HIV‐Infected Persons Is Associated With Earlier Adoption of New Antiretroviral Therapy , 2000, Journal of acquired immune deficiency syndromes.

[25]  D. Costagliola,et al.  Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor , 2000, AIDS.

[26]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[27]  Mardge H. Cohen,et al.  Erratum: The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: Results of the women's interagency HIV study (AIDS (1999) 13 (1717-1726)) , 2000 .

[28]  B. Ledergerber,et al.  Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. , 1999, AIDS research and human retroviruses.

[29]  L A Kalish,et al.  The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study. , 1999, AIDS.

[30]  Albert Wu,et al.  Optimizing Care for Persons with HIV Infection , 1999, Annals of Internal Medicine.

[31]  R. Chaisson,et al.  Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.

[32]  D Johnson,et al.  The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. , 1999, AIDS.

[33]  A. Telenti,et al.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.

[34]  M. Fletcher,et al.  Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an Urban Veterans Affairs Medical Center. , 1999, Journal of acquired immune deficiency syndromes.

[35]  A. Wu,et al.  Optimizing care for persons with HIV infection. Society of General Internal Medicine AIDS Task Force. , 1999, Annals of internal medicine.

[36]  H. Ullum,et al.  The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection , 1998, AIDS.

[37]  J. Montaner,et al.  The effects of lamivudine treatment on HIV‐1 disease progression are highly correlated with plasma HIV‐1 RNA and CD4 cell count , 1998, AIDS.

[38]  M C Weinstein,et al.  The cost-effectiveness of preventing AIDS-related opportunistic infections. , 1998, JAMA.

[39]  J. Margolick,et al.  Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. , 1998, JAMA.

[40]  M. Hughes,et al.  Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response , 1997, Annals of Internal Medicine.

[41]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[42]  S. Hammer,et al.  The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. , 1996, The New England journal of medicine.

[43]  J. Callen.  Ability of primary care physicians to recognize physical findings associated with HIV infection , 1996 .

[44]  H. Welch,et al.  Estimating Treatment Benefits for the Elderly: The Effect of Competing Risks , 1996, Annals of Internal Medicine.

[45]  S. Shaunak,et al.  Combining specialist and primary health care teams for HIV positive patients: retrospective and prospective studies , 1996, BMJ.

[46]  J. Carline,et al.  Physicians' ability to provide initial primary care to an HIV-infected patient. , 1995, Archives of internal medicine.